GleamWall
中文EN

RKTO Rocket One Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1711786 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY2.2%
TTM EPS YoY40.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-152.0%
ROA-132.9%
ROIC (approx.)-1,024.5%
Asset turnover—

Leverage & solvency

Liabilities / assets14.3%
Debt / equity0.00x
Current ratio5.55x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.92x
Accruals ratio-10.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$5.95M$3.25M
SG&A expense$6.41M$4.97M
Operating income-$12.36M-$8.22M
Pretax income-$12.40M-$8.11M
Net income-$12.47M-$8.19M
EPS (basic)-0.90-1.28
EPS (diluted)-0.90-1.28
Weighted avg. shares (diluted)13.81M6.38M
Balance sheet
Cash & equivalents$6.25M$7.04M
Current assets$6.86M$7.64M
Total assets$7.60M$7.71M
Current liabilities$1.45M$831,197
Total liabilities$1.45M$833,906
Shareholders' equity$6.15M$6.88M
Shares outstanding15.51M8.04M
Cash flow statement
Operating cash flow-$9.80M-$6.98M
Investing cash flow-$300,000—
Financing cash flow$9.31M$4.74M
Stock-based compensation$1.19M$804,277

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.